233 related articles for article (PubMed ID: 28424422)
21. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
[TBL] [Abstract][Full Text] [Related]
22. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
23. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
[TBL] [Abstract][Full Text] [Related]
24. Incorporation of molecular characteristics into endometrial cancer management.
Vermij L; Smit V; Nout R; Bosse T
Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
[TBL] [Abstract][Full Text] [Related]
25. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
Dellinger TH; Smith DD; Ouyang C; Warden CD; Williams JC; Han ES
Gynecol Oncol; 2016 May; 141(2):336-340. PubMed ID: 26861585
[TBL] [Abstract][Full Text] [Related]
26. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Vermij L; Jobsen JJ; León-Castillo A; Brinkhuis M; Roothaan S; Powell ME; de Boer SM; Khaw P; Mileshkin LR; Fyles A; Leary A; Genestie C; Jürgenliemk-Schulz IM; Crosbie EJ; Mackay HJ; Nijman HW; Nout RA; Smit VTHBM; Creutzberg CL; Horeweg N; Bosse T;
Br J Cancer; 2023 Mar; 128(7):1360-1368. PubMed ID: 36690721
[TBL] [Abstract][Full Text] [Related]
27. L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma.
Romani C; Capoferri D; Reijnen C; Lonardi S; Ravaggi A; Ratti M; Bugatti M; Zanotti L; Tognon G; Sartori E; Odicino F; Calza S; Pijnenborg JMA; Bignotti E
Int J Cancer; 2022 Aug; 151(4):637-648. PubMed ID: 35429348
[TBL] [Abstract][Full Text] [Related]
28. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
[TBL] [Abstract][Full Text] [Related]
30. Pathology of Endometrial Carcinoma.
Lax SF
Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
[TBL] [Abstract][Full Text] [Related]
31. Addition of IMP3 to L1CAM for discrimination between low- and high-grade endometrial carcinomas: a European Network for Individualised Treatment of Endometrial Cancer collaboration study.
Visser NCM; van der Putten LJM; van Egerschot A; Van de Vijver KK; Santacana M; Bronsert P; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Krakstad C; Tangen IL; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Hausnerova J; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Trovik J; Amant F; Massuger LFAG; Bulten J; Pijnenborg JMA
Hum Pathol; 2019 Jul; 89():90-98. PubMed ID: 31054899
[TBL] [Abstract][Full Text] [Related]
32. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy.
Bakhsh S; Kinloch M; Hoang LN; Soslow RA; Köbel M; Lee CH; McAlpine JN; McConechy MK; Gilks CB
Histopathology; 2016 May; 68(6):916-24. PubMed ID: 26416160
[TBL] [Abstract][Full Text] [Related]
33. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
[TBL] [Abstract][Full Text] [Related]
34. The Prediction of Recurrence in Low-Risk Endometrial Cancer: Is It Time for a Paradigm Shift in Adjuvant Therapy?
Laban M; El-Swaify ST; Ali SH; Refaat MA; Sabbour M; Farrag N; Hassanin AS
Reprod Sci; 2022 Apr; 29(4):1068-1085. PubMed ID: 33856667
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutation in endometrial carcinoma and hyperplasia: correlation with KRAS and p53 mutations and mismatch repair protein expression.
Feng YZ; Shiozawa T; Miyamoto T; Kashima H; Kurai M; Suzuki A; Konishi I
Clin Cancer Res; 2005 Sep; 11(17):6133-8. PubMed ID: 16144912
[TBL] [Abstract][Full Text] [Related]
36. Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study.
Lüchtenborg M; Weijenberg MP; Wark PA; Saritas AM; Roemen GM; van Muijen GN; de Bruïne AP; van den Brandt PA; de Goeij AF
BMC Cancer; 2005 Dec; 5():160. PubMed ID: 16356174
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.
Cosgrove CM; Cohn DE; Hampel H; Frankel WL; Jones D; McElroy JP; Suarez AA; Zhao W; Chen W; Salani R; Copeland LJ; O'Malley DM; Fowler JM; Yilmaz A; Chassen AS; Pearlman R; Goodfellow PJ; Backes FJ
Gynecol Oncol; 2017 Sep; 146(3):588-595. PubMed ID: 28709704
[TBL] [Abstract][Full Text] [Related]
38. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment.
Leon-Castillo A; Horeweg N; Peters EEM; Rutten T; Ter Haar N; Smit VTHBM; Kroon CD; Boennelycke M; Hogdall E; Hogdall C; Nout RRA; Creutzberg CL; Ortoft G; Bosse T
Gynecol Oncol; 2022 Mar; 164(3):577-586. PubMed ID: 35078648
[TBL] [Abstract][Full Text] [Related]
39. Intratumor heterogeneity in hepatocellular carcinoma.
Friemel J; Rechsteiner M; Frick L; Böhm F; Struckmann K; Egger M; Moch H; Heikenwalder M; Weber A
Clin Cancer Res; 2015 Apr; 21(8):1951-61. PubMed ID: 25248380
[TBL] [Abstract][Full Text] [Related]
40. Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
Perrone E; Capasso I; De Felice F; Giannarelli D; Dinoi G; Petrecca A; Palmieri L; Foresta A; Nero C; Arciuolo D; Lorusso D; Zannoni GF; Scambia G; Fanfani F
Eur J Cancer; 2023 Jun; 186():98-112. PubMed ID: 37062213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]